• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)
ConclusionsThese results suggest that rivaroxaban is an effective and safe treatment option among NVAF patients with obesity and polypharmacy in a commercially-insured US population.
Source: Advances in Therapy - May 25, 2021 Category: Drugs & Pharmacology Source Type: research

Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States
ConclusionIn the real-world setting, patients with NVAF newly treated with apixaban were less likely to switch or discontinue treatment compared to patients treated with rivaroxaban or dabigatran.FundingPfizer and Bristol-Myers Squibb.
Source: Advances in Therapy - November 29, 2018 Category: Drugs & Pharmacology Source Type: research

Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel Disease
ConclusionsPatients with IBD experienced greater rates of DVT and PE compared to patients without IMD; this elevated risk was associated with a substantial economic burden.
Source: Advances in Therapy - December 7, 2021 Category: Drugs & Pharmacology Source Type: research

Real-World Racial Variation in Treatment and Outcomes Among Patients with Peripheral Artery Disease
ConclusionsResults of this real-world study suggest that Black patients with PAD have higher disease severity at the time of diagnosis and are at increased risk of experiencing adverse outcomes following diagnosis.
Source: Advances in Therapy - March 6, 2023 Category: Drugs & Pharmacology Source Type: research

Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme
ConclusionGlobally, CKD carries a significant economic burden, which increases substantially with increasing disease severity. We identified significant gaps in published costs and inconsistent costing definitions. Cost-effective interventions that target primary prevention and disease progression are essential to reduce CKD burden. Our results can be used to guide cost collection and facilitate better comparisons across countries/regions to inform healthcare policy.
Source: Advances in Therapy - July 26, 2023 Category: Drugs & Pharmacology Source Type: research